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Background. Findings on the association between posttransplant anemia (PTA) and mortality in posttransplant patients are scarce.
This study explored whether PTA shortly after kidney transplantation (KT) predicts mortality at up to 10 years’ follow-up, stratified
for chronic kidney disease (CKD) stages. Methods. PTA was divided into 3 categories according to the hemoglobin (Hb) value:
severe (Hb < 10 g/dl), mild (10.0 g/dl ≤ Hb < 11.9 g/dl), or no PTA (Hb ≥ 12 g/dl). CKD stages were estimated using the CKD-EPI
formula and divided into 2 groups: CKD1-2 and CKD3–5. Cox regression, stratified according to CKD, was performed to identify
whether different categories of PTA predicted mortality in KT recipients. Results. Age, being female, and both mild and severe
PTA contributed significantly to the Cox regression model on mortality in CKD1-2. In the Cox regression model for mortality
in CKD3–5, age and severe PTA contributed significantly to this model. Conclusion. PTA shortly after KT increased the risk of
mortality at up to 10 years’ follow-up. Even mild PTA is associated with a 6-fold higher risk of mortality and severe PTA with a
10-fold higher risk of mortality in CKD1-2. Clinical evaluation and treatment of anemia might reduce the higher risk of mortality
in patients with PTA in early stages of CKD after KT.
1. Introduction
Thedefinition and grades of anemia were established decades
ago by the World Health Organization (WHO) as being
among the important factors influencing health outcomes:
decreased hemoglobin concentration predicts morbidity and
mortality in the general population [1], and this definition
was consequently adopted by nephrologists. According to
“The National Kidney Foundation Disease Outcomes Qual-
ity Initiative” (NKF/KDOQI), “Kidney Disease Improving
Global Outcomes” (KDIGO), and “European Best Practice
Guidelines” (EBPG), anemia is defined as a target hemoglobin
(Hb) <13.5 g/dl in adult males/postmenopausal females,
<12.0 g/dl in premenopausal females, and <5th percentile for
children [2–4]; alternatively, the target Hb should generally
be <11.0 g/dl [5, 6].
However, in most individuals there is a considerable
amount of variation in theHb-value over time, and the conse-
quences of this variability in Hb-levels have been thoroughly
studied in dialysis patients, though not in transplant recipi-
ents [7]. Renal anemia after transplantation, or posttransplant
anemia (PTA), has a multifactorial etiology including the
progress of transplant kidney failure, comorbidity, infections,
inflammation, angiotensin-converting enzyme inhibitor/
angiotensin receptor blocker (ACEi/ARB), and immunosup-
pressive treatment [2–6, 8–10]. Thus far, some evidence has
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Figure 1: Flow-chart diagram of the participants.𝑁/𝑛: number; RR: response rate; KT: kidney transplantation; PTA: posttransplant anemia.
been found suggesting that kidney-transplant recipients may
have Hb-level lower than what can be expected based on the
level of their kidney function [2].
Guidelines from NKF/KDOQI, KDIGO, and EBPG rec-
ommend treating anemia of renal origin in order to reduce
both morbidity and mortality [2–5]. KDIGO guidelines for
kidney-transplant recipients state that treatment should be
directed at the underlying cause. In contrast, regular testing
for anemia is not recommended by the above-mentioned
guidelines, and treatment of posttransplant anemia should
be managed according to the guidelines for chronic kidney
disease (CKD) in the predialysis period, with no specific
recommendation for treatment of this specific population [2].
Additionally, the impact of the variability of hemoglobin
over time in transplant recipients as compared with dialyzed
patients has been considered in only a few studies. Some
relationships between rejection episodes, immunosuppres-
sant use, and increased anemia prevalence [9, 10], as well as
between anemia of renal origin and mortality [11–13], have
been shown.
Renal anemia after transplantation and its association
with transplant outcomes have not been sufficiently explored;
moreover, longitudinal studies on the association between
anemia and mortality are rather rare, and PTA is still an
underestimated problem [7, 13–15]. Therefore, the aim of this
study was to explore whether anemia shortly after kidney
transplantation predictsmortality at up to 10 years’ follow-up.
2. Materials and Methods
2.1. Sample and Procedure. A total of 362 consecutive patients
who underwent KT between January 2001 and January 2011
at the Transplant Centre of Kosice in the eastern region of
Slovakia were enrolled in the study. The presented findings
are part of a bigger study focused on quality of life measured
using several questionnaires; the collection of medical data
for this study took place during the collection of the ques-
tionnaires. The baseline examination of the participants took
place between the 3rd and 12th month after successful KT
during regular outpatient clinical visits in our centre. The
inclusion criterion was graft survival at 3 months after KT,
because the first 3 months after KT are usually considered
as the most problematic period associated with dramatic
changes and increased morbidity and even mortality [16]. All
recipients were previously included on the waiting list for a
kidney transplant. Therefore, they were tested for all serious
comorbidities, such as cancer, which is always an exclusion
criterion for transplantation; thus, no transplanted recipients
had a cancer diagnosis at baseline. Additionally, the degree
of renal anemia during a period shorter than 3 months after
successful transplantation depends on the pre- and peritrans-
plantation period [2]. In the case of any severe medical prob-
lem (infection, rejection, surgery, etc.) data collection was
postponed by one month after overall clinical stabilization.
Nine patients dropped out prior to reaching 3 months
after transplantation: 3 (0.8%) died and 6 (1.7%) lost their
transplanted kidney. In total 353 kidney-transplant recipients
after successful transplant surgery were invited to participate.
Out of these, 35 (9.9%) refused to participate, resulting in a
total of 318 patients (an effective response rate of 90.1%) at the
start of the study. Figure 1 presentsmore detailed information
about the sample (Figure 1). Only patients who signed an
informed consent form prior to the study were included.The
Institutional Ethics Committee of the University Hospital in
Kosice approved the study. All data and information used
from the documentation, including demographic and clinical
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ones, were used in accordance with the ethical standards as
laid down in the 1964 Declaration of Helsinki and its later
amendments or comparable ethical standards.
2.2. Measures
2.2.1. Sociodemographic Data. Sociodemographic data
included age and gender. Age was treated as a continuous
variable. Male gender was the reference category.
2.2.2. Clinical Data. Clinical data were retrieved from med-
ical files. These included serum hemoglobin, creatinine
(laboratory methods by Scheffe), primary kidney diagnosis,
previous duration of dialysis (in years), source of transplanted
kidney, comorbidities, current and antirejection immuno-
suppressive treatment, acute rejection episodes, chronic
renal allograft dysfunction, uroinfection (which included
pyelonephritis and diagnosis of graft loss), andmortality.The
estimated glomerular filtration rate (eGFR) was calculated
using the CKD-EPI formula in milliliters per minute and
1.73m2 [17]. CKD stages were determined as recommended
by the “Kidney Disease Initiative for Global Outcomes”
(KDIGO) guideline. This proposes a classification of chronic
kidney disease [2, 6]; the classification reflects the impact of
CKD (stages) for risk evaluation, diagnosis, patient manage-
ment, and treatment options. In order to explore the effect of
the CKD stages on anemia, we stratified the sample into two
groups, as groups consisting of the separate CKD stages were
too small for stratification: CKD stages 1-2 versus CKD stages
3–5, according to the known impact of deceased kidney func-
tion on increasing anemia of renal origin from CKD stage 3
[2, 6]. Acute rejection episodes and chronic renal allograft
dysfunction were diagnosed from a biopsy according to the
Banff 2009 update of diagnostic categories for renal allograft
biopsies [18]. Depending on the hemoglobin value, PTA was
divided into 3 categories: (1) severe PTA (Hb< 10 g/l), (2)mild
PTA (10 ≤Hb < 12 g/l), and (3) no PTA (Hb ≥ 12 g/dl) accord-
ing to the “European Renal Best Practice” (ERBP) Guidelines
[3, 4]. Severe cardiac failure was classified by the New
York Heart Association (NYHA) Functional Classification as
Classes III and IV [19].
2.2.3. Mortality Data. Mortality data were obtained from our
database ofmedical reports and completedwith data from the
“Health Care Surveillance Authority of the Slovak Republic”
up to 10 years after KT.
2.3. Statistical Analyses. Frequencies, means, and standard
deviations were calculated for the sample description. The
Mann–Whitney 𝑈 test and 𝜒2 test were used to identify
the association between mortality and the following baseline
variables: age, gender, duration on dialysis before KT (in
years), eGFR and CKD stages, PTA (severe, mild, and
no anemia, which was the reference category), uroinfec-
tion (pyelonephritis included), number of acute rejection
episodes, chronic renal allograft dysfunction, source of
transplanted kidney, cardiovascular disease (coronary artery
disease, cardiac failure, myocardial infarction), hypertension,
and categories of diabetes mellitus (no diabetes mellitus,
already existing diabetes mellitus, and new-onset diabetes
mellitus after transplantation). Stratification by CKD was
performed with regard to the known impact of decreased
kidney function on anemia of renal origin [6] in order
to study the potentially different associations between PTA
and other incorporated variables independently of kidney
function.These variables were included in the analysis due to
the past research evidence outlined in the Introduction [2, 5].
Kaplan–Meier plots and log-rank test were used to display
the differences between mortality risks by PTA categories
separately for CKD stages 1-2 compared to CKD stages 3–5.
Cox regressionwas performed in order to identify the predic-
tors of mortality (censored for graft loss). The independent
variables in both stratified Cox regression models were all
variables with a level of significance set at 𝑝 < 0.1 in the
Mann–Whitney 𝑈 test and the 𝜒2 test, as appropriate. The
Statistical Package for the Social Science (IBM SPSS Inc.,
Chicago, IL, USA) version 24 was used for statistical analyses.
3. Results
No significant differences were found at baseline between
participants and nonparticipants regarding age, gender, graft
loss, and mortality. The observation period of follow-up was
from 1 to 10 years (mean 5.6 ± 2.7); the mean period for
severe PTA was 4.3 ± 2.6 years, for mild PTA 5.3 ± 2.6 years,
and for the category without PTA 5.9 ± 2.7 years. The preva-
lence of renal anemia therapy was 14% with Erythropoiesis-
Stimulating Agents (ESA), 48% iron supplementation, 33%
folic acid, 14% ascorbic acid, 10% pyridoxine, and 6% cobal-
amin. Table 1 displays detailed information about the charac-
teristics of the sample (𝑁 = 318) (Table 1).
The Mann–Whitney 𝑈 test found that those who died
were older (𝑝 < 0.001) and had a lower eGFR (𝑝 < 0.001)
in the first year after KT. 𝜒2 test indicated that they were also
more likely to be of female gender (𝑝 < 0.1), to have a higher
degree of PTA (𝑝 < 0.001), to have a more advanced stage of
CKD (𝑝 < 0.001), and to show the presence of severe cardiac
failure (𝑝 < 0.1) in the first year after KT (Table 1).The risk of
death in patients with mild and severe PTA in CKD stages 1-2
compared with no PTA starts to rise at 3 years after KT; the
hazard ratio for mild and severe PTA compared with no PTA
increased after this period independently of kidney function.
However, the risk of death in patients with severe PTA in
CKD stages 3–5 starts to rise already at 2 years after KT.
Figures 2 and 3 display the differences in mortality between
those with severe PTA, those with mild PTA, and those with
no PTA. (Figures 2 and 3).
3.1. Model 1: Cox RegressionModel forMortality in CKD Stages
1-2. Age (HR 1.1, 𝑝 ≤ 0.001), female gender (HR 0.1, 𝑝 ≤
0.05), mild PTA (HR 6.2, 𝑝 ≤ 0.05), and severe PTA (HR 9.8,
𝑝 ≤ 0.001) contributed significantly to Cox regression model
1 for mortality in CKD stages 1-2. The risk of death increased
by 10% for each year of age, while, on the other hand, the risk
of death decreased by 90% among females. In addition, the
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Table 1: Characteristics of the sample (𝑁 = 318).
Characteristics of the sample at baseline Died after transplant (𝑛 = 51) Survived after transplant (𝑛 = 267) 𝑝 value
𝑛 (%) or mean ± SD 𝑛 (%) or mean ± SD
Age 48.4 ± 6.8 46.9 ± 7.4 0.001
Gender
Male 24 (47.1%) 159 (59.6%) 0.05
Female 27 (52.9%) 108 (40.4%)
Duration on dialysis before KT (in years) 3.7 ± 2.1 3.5 ± 2.9 n.s.
Primary diagnosis of kidney failure
Glomerulonephritis 19 (37.3%) 96 (36.0%)
n.s.
Tubulointerstitial nephritis 12 (23.5%) 66 (24.7%)
Vascular disease 3 (5.9%) 28 (10.5%)
Polycystic kidneys adult type 2 (3.9%) 19 (7.1%)
Diabetic nephropathy 8 (15.7%) 13 (4.9%)
Others or unknown 7 (13.7%) 45 (16.8%)
Source of transplanted kidney
Deceased donor 47 (92.2%) 256 (95.9%) n.s.
Living donor 4 (7.8%) 11 (4.1%)
Function immediately after KT
Immediate function 27 (52.9%) 150 (56.2%) n.s.
Delayed function 24 (47.1%) 117 (43.8%)
Estimated glomerular filtration rate (ml/min/1.73m2) 61.2 ± 19.8 63.8 ± 20.1 0.001
CKD stage
1 5 (9.8%) 18 (6.7%)
0.07
2 20 (39.2%) 115 (43.2%)
3a + 3b 21(41.2%) 101 (37.8%)
4 3 (5.9%) 11 (4.1%)
5 2 (3.9%) 22 (8.2%)
Hemoglobin value (g/dl) 11.9 ± 1.9 12.7 ± 2.1 0.001
Posttransplant anemia
Severe (Hb < 10.0 g/dl) 8 (15.8%) 19 (7.1%)
0.001Mild (10.0 ≤Hb < 12.0 g/dl) 17 (33.3%) 55 (20.6%)
No anemia (Hb 12.0 g/dl) 26 (50.9%) 193 (72.3%)
Therapy for anemia
ESA 3 (5.9%) 11 (4.1%)
n.s.
Iron 8 (15.7%) 39 (14.6%)
Folic acid 14 (27.4%) 19 (7.1%)
Cobalamin 2 (3.9%) 4 (1.5%)
Pyridoxine 1(2.0%) 9 (3.4%)
Ascorbic acid 3 (5.9%) 11 (4.1%)
Acute rejection episodes 17 (33.3%) 78 (29.2%) n.s.
Type of rejection treatment
Steroids 9 (17.6%) 63 (23.6%)
n.s.Antithymocyte globulin 2 (3.9%) 8 (3.0%)
Plasmapheresis 1(2.0%) 5 (1.9%)
Plasmapheresis + i.v. immunoglobuline 1(2.0%) 6 (2.2%)
Chronic renal allograft dysfunction 8 (15.7%) 34 (12.7%) n.s.
Uroinfection (including pyelonephritis of graft) 14 (27.4%) 71 (26.6%) n.s.
Immunosuppression treatment
CsA + P 7 (13.7%) 29 (10.9%)
n.s.
CsA + AZA/CsA + AZA + P 8 (15.7%) 16 (6.0%)
CsA + MMF/CsA + MMF + P 23 (45.1%) 131 (49.0%)
Tac + MMF/Tac + MMF + P 11 (21.6%) 86 (32.2%)
SIR + MMF + P/EVER + CsA + MMF 2 (3.9%) 5 (1.9%)
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Table 1: Continued.
Characteristics of the sample at baseline Died after transplant (𝑛 = 51) Survived after transplant (𝑛 = 267) 𝑝 value
𝑛 (%) or mean ± SD 𝑛 (%) or mean ± SD
Comorbidities
Coronary artery disease 11 (21.6%) 67 (25.1%) n.s.
Severe cardiac failure 15 (29.4%) 57 (21.3%) 0.09
Myocardial infarction 3 (5.9%) 14 (5.2%) n.s.
Hypertension 37 (72.5%) 189 (70.8%) n.s.
Diabetes mellitus identified before KT 8 (15.7%) 22 (8.2%) n.s.
NODAT 3 (5.9%) 14 (5.2%) n.s.
CKD-MBD 23 (45.1%) 140 (52.4%) n.s.
Other comorbidities: ≥2 1(2.0%) 8 (3.0%) n.s.
Level of significance 𝑝 < 0.1;𝑁/𝑛: number, SD: standard deviation, AZA: azathioprine, CKD: chronic kidney disease, MBD: mineral bone disorder, NODAT:
new-onset diabetesmellitus after transplantation,CsA: cyclosporineA, ESA: erythropoiesis-stimulating agents, EVER: everolimus,Hb: hemoglobin,KT: kidney
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Figure 2: Differences in mortality between severe PTA, mild PTA,
and no PTA over 10 years in CKD stages 1-2. Kaplan–Meier plots
showing higher mortality during 10 years after transplantation in
patients with CKD stages 1-2 with mild or severe anemia compared
with patients without PTA. Log-rank test: 𝜒2 = 39.62 and 𝑝 value of
the model < 0.001.
presence of mild PTA increased the risk 6-fold and severe
PTA 10-fold (Table 2).
3.2. Model 2: Cox Regression Model for Mortality in CKD
Stages 3–5. Age (HR 1.1, 𝑝 ≤ 0.01) and severe PTA (HR 10.8,
𝑝 ≤ 0.001) contributed significantly to Cox regression model
2 for mortality in CKD stages 3–5.The risk of death increased
by 10% for each year of age, and the presence of severe PTA
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Figure 3: Differences in mortality between severe PTA, mild PTA,
and no PTA over 10 years in CKD stages 3–5. Kaplan–Meier plots
showing higher mortality during 10 years after transplantation in
patients with CKD stages 3–5 with severe PTA compared with
patients without PTA. Log-rank test: 𝜒2 = 32.09 and 𝑝 value of the
model < 0.001.
4. Discussion
We explored the independent effect of anemia onmortality in
the early period after kidney transplantation.Mild and severe
PTA in the first year after transplantation increased the higher
risk of mortality independently of kidney function at up to 10
years’ follow-up. Mild PTA predicted a 6-fold higher risk of
mortality and severe PTA a 10-fold higher risk of mortality
compared with no PTA in CKD stages 1-2. However, patients
with more advanced stages of CKD showed no association of
mild PTA with mortality, probably as this only reflects their
6 BioMed Research International
Table 2: Final models of Cox regression [stratified due to 2 CKD
groups (CKD stages 1-2 and 3–5)] containing predictors ofmortality.
Models for mortality
(𝑁 = 318) HR
95% CI for
HR 𝑝 value
Model 1 in CKD stages
1-2 (𝑛 = 158)
Age 1.12 1.05; 1.20 0.000
Gender
Male Reference
Female 0.09 0.09; 0.82 0.033
Severe cardiac failure
No Reference
Yes 1.82 0.60; 4.23 0.316
PTA
No Reference
Mild 6.16 1.12; 34.33 0.038
Severe 9.79 2.57; 37.26 0.001
Model 2 in CKD stages
3–5 (𝑛 = 160)
Age 1.06 1.02; 1.09 0.003
Gender
Male Reference
Female 0.59 0.29; 1.20 0.593
Severe cardiac failure
No Reference
Yes 1.92 0.82; 5.56 0.835
PTA
No Reference
Mild 1.29 0.56; 2.98 0.554
Severe 10.78 4.15; 28.08 0.000
PTA: posttransplant anemia, CI: Confidence Interval, HR: hazard ratio.
worse kidney function; however, severe PTA predicted a 10-
fold higher risk of mortality. The other factor associated with
increased risk of mortality was advanced age and that with
decreased mortality was female gender, which is in line with
the other studies [20, 21].
NKF/KDOQI and KDIGO guidelines for diagnosis and
treatment of renal anemia recommend a global assessment of
the patient, which should consist of an inventory of complica-
tions of the dialyzed, perioperative, and posttransplantation
period, including inflammatory diseases, rejections, comor-
bidities, ACEi/ARB, and immunosuppressant treatment [2,
3, 6]. In our study uroinfection (including pyelonephritis),
rejection episodes, chronic renal allograft dysfunction, car-
diovascular disease, already existing diabetes mellitus, new-
onset diabetes mellitus after transplantation, and the total
number of other comorbidities were not associated with
mortality in patients after KT.
In line with our results, Amaral et al. showed that patients
with mild and severe anemia of renal origin independently of
CKD had an increased risk for mortality [22]. A few other
studies have also shown that a low level of Hb is strongly
associated with mortality [7, 12, 13]. In our sample, 31.1% of
respondents had various grades of anemia, fitting in the range
from 20 to 57%, as was found earlier for Central Europe [23].
The study of Lawler et al. (2010), with CKD in the predia-
lyzed period, showed that anemia in this group was underes-
timated, with an absence of relevant blood tests and a lack of
treatment [24]. Iseki and Kohagura showed that renal anemia
is a marker of kidney failure and is associated with a higher
incidence of stroke and heart failure and relevant lower qual-
ity of life and survival [25]. Regarding the above-mentioned
outcomes, Amaral et al. suggested that the hazard ratio of
mortality is increased proportionally according to the sever-
ity of the anemia. They discovered that a serum hemoglobin
concentration of 11.0 g/dl andhigher showed a 60–70% reduc-
tion in the risk of mortality [22].
The prevalence of renal anemia treatment after KT is,
according to theNKF/KDOQI guidelines, relevant to CKD in
the predialyzed period [5]. Surprisingly, Molnar et al. found
in ten renal transplant units across Europe that the prevalence
and management practices related to renal anemia after
transplantationwere quite variable and overall have remained
largely unchanged over the last 5 years [11]. In our sample,
more than two-thirds of the patients were treated by a combi-
nation of two drugs. Similar to our results, Spiegel and Cher-
tow (2009) showed the benefit of renal anemia treatment by
ESA and iron therapy [8].
The most recent studies regarding renal anemia therapy
have shown that there is a narrow boundary between safe
treatment and therapy causing increased morbidity and
mortality risk [26]. Reports on the relative adequate serum
concentration of hemoglobin and iron and other essential
components have shown a higher risk of stroke, thrombosis,
and progression of cancer [26, 27]. These conclusions bring
up newquestions about dosing algorithms aimed at achieving
and maintaining optimal target hemoglobin levels without
endangering the patient.
4.1. Strengths and Limitations. The main strength of this
study is the prospective follow-up for 10 years, which enabled
us to explore anemia and other factors as predictors of mor-
tality in kidney-transplant recipients. Moreover, all consec-
utive patients originating from one major transplant centre
in Slovakia over a number of years were asked to participate
in the study to prevent selection bias. Additional strengths
of this study are the exclusion of problems in the first 3
months, the long follow-up, and the exclusion of preexisting
cardiovascular disease and rejection episodes. Moreover, this
study compares the PTA impact on mortality separately for
well-functioning graft versus advanced stages of CKD and
addresses the underreporting and undertreating of renal
anemia in patients with a well-functioning graft (CKD1-2).
Thefindings demonstrated the ability of usingPTA inpatients
with a well-functioning graft for predicting mortality.
In contrast, stratification of the sample into only two
groups according to CKD stages is the main limitation of this
study. We were unable to compare each CKD stage regarding
the mortality prediction by anemia separately due to the
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low number of participants in CKD stages four and five.
Additionally, the level of PTA was based on the Hb-value
at baseline. The next limitation of the study might be the
lack of certain other biomarkers (serum concentration of
ESA, iron, ferritin, transferrin, vitamins, etc.) and additional
information (inflammatory markers, catabolism). These fac-
tors, therapy, and inflammatory markers are associated with
a decrease in the hemoglobin value; in addition, they play an
important role in exploring the causes of PTA and in its inci-
dence.Therefore, these factors have to be considered in future
research.The variable observation period betweenminimum
and maximum (1 and 10 years) is also a limitation. Testing
for anemia in this study was not conducted immediately after
transplantation to prevent false findings due to perioperative
complications. Therefore, patients who died or lost their
transplanted kidney within the first 3 months after KT were
not included in the study. It could be of interest to control for
a potential effect of pretransplantation anemia and potential
progression of PTA, as they may predict mortality and graft
loss, as well.
4.2. Recommendations. Our findings imply that mild and
severe anemia in CKD stages 1-2 may be an independent
element of the pathway to survival in kidney-transplant recip-
ients. In line with our results, we suggest treating mild and
severe anemia in patients after the thirdmonth following suc-
cessful transplantation to increase their probability for sur-
vival. Further studies should also be carried out to shed more
light on this important pathway. It would be worthwhile to
plan a similar study based on the individual CKD stages in the
future. According to these results, a randomized controlled
trial in ESA treatment of posttransplant anemia with a target
Hb-value above 10.0 g/dl would be appropriate. We could
then verify whether treatment of anemia after KT decreases
mortality in kidney-transplant recipients and thus fills a gap
in the guidelines for ESA in posttransplant anemia regarding
the Hb-value. Furthermore, the pathways between other
medical determinants associated with anemia and mortality
should be studied as well.
5. Conclusion
Posttransplant anemia in an early period after transplantation
increased the risk of mortality independently of kidney func-
tion at up to 10 years’ follow-up in CKD stages 1-2. Mild PTA
is associated with a 6-fold higher risk of mortality and severe
PTAwith a 10-fold higher risk of mortality compared with no
PTA inCKD stages 1-2.Thus, patients with awell-functioning
transplanted kidney but with posttransplant anemia might
benefit from clinical evaluation as well as treatment (e.g.,
Erythropoiesis-Stimulating Agents, iron therapy) to reduce
their higher risk of mortality. However, patients with more
advanced stages of CKD showed no association of mild PTA
with mortality, probably as this may only reflect their worse
kidney function; however, severe PTA predicted a 10-fold
higher risk of mortality.
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